What's New in the Management of Hormone Naïve & Castrate Resistant Prostate Cancer: A Case-based Session for Urologists, Advanced Practice Providers and Teams Webcast (2021)

CME Available: [ Ссылка ]

At the conclusion of this course, participants will be able to:
1. List the three main advanced prostate cancer disease states (HSMPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice.
2. Identify FDA-hormonal and non-hormonal therapies for use in each of these three disease states: HSMPC, M0 CRPC, M1 CRPC.
3. Demonstrate the safe use and unique mechanism of action and side effects of new and existing agents.
4. Explain the sequencing of novel therapies and be able to identify patient progression of disease by PSA, imaging and signs and symptoms.
5. Work in team care including urologists, advanced practice providers, oncology nursing, oncology pharmacy, medical oncology and radiation oncology and their support staffs.

ACKNOWLEDGEMENTS
Independent educational grant support provided by:
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Exact Sciences Corporation
Janssen Biotech, Inc. Administered by Janssen Scientific Affairs, LLC
Merck
Pfizer, Inc.
Sanofi Genzyme

свернуть